Wroclaw Medical University, Wroclaw, Poland.
J Am Coll Cardiol. 2013 Oct 8;62(15):1330-8. doi: 10.1016/j.jacc.2013.06.043. Epub 2013 Jul 31.
The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).
Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.
Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial. Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.
The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004). Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group. Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.
In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity. Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful. (Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).
本研究旨在检验伊伐布雷定治疗射血分数保留心力衰竭(HFpEF)患者的运动能力和左心室充盈的效果。
HFpEF 的症状通常与体力活动相关,通过控制心率优化舒张充盈时间可能会延迟症状的发生。
在这项双盲试验中,61 名 HFpEF 患者被随机分为伊伐布雷定 5mg,每日两次(n=30)或安慰剂(n=31)组,连续治疗 7 天。在静息和运动后进行心肺运动测试,并进行超声心动图评估心肌功能和左心室充盈。
伊伐布雷定组在运动能力(4.2±1.8 METs 与 5.7±1.9 METs,p=0.001)和峰值摄氧量(14.0±6.1ml/min/kg 与 17.0±3.3ml/min/kg,p=0.001)方面均有显著改善,同时运动诱导的峰值早期二尖瓣血流速度与峰值早期二尖瓣环速度比值也降低(3.1±2.7 与 1.3±2.0,p=0.004)。负荷校正变时反应(在基线和随访测试中同一运动时间的心率差异)显示,运动时心率的增加比安慰剂组慢。伊伐布雷定治疗(β=0.34,p=0.04)和治疗后运动时峰值早期二尖瓣血流速度与峰值早期二尖瓣环速度比值的增加(β=-0.30,p=0.02)与运动能力的增加呈独立相关,伊伐布雷定治疗(β=0.32,p=0.007)与峰值摄氧量的增加呈独立相关。
在 HFpEF 患者中,短期伊伐布雷定治疗可增加运动能力,改善左心室充盈压力对运动的反应,这反映在峰值早期二尖瓣血流速度与峰值早期二尖瓣环速度比值上。由于该患者群体在体力活动时出现症状,针对异常运动血液动力学状态的治疗方法可能会有用。(使用运动和医疗治疗改善因肺充血导致呼吸困难的患者的心脏功能;ACTN12610001087044)。